Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples

• US 20110045471A1
• Filed: 09/14/2008
• Published: 02/24/2011
• Est. Priority Date: 10/11/2007
• Status: Abandoned Application

• Current Assignee: Genesis Genomics Inc
• Original Assignee: Genesis Genomics Inc
• Inventors: Harbottle, Andrew, Parr, Ryan, Creed, Jennifer, Maki, Katrina, Robinson, Kerry, Birch-Machin, Mark, Maggrah, Andrea, Dakubo, Gabriel, Reguly, Brian, Thayer, Robert
• Application Number:
  US12/682,338
• Publication Number:
  US 20110045471A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers

Abstract

The present invention relates to methods for predicting, diagnosing and monitoring skin states and skin diseases. The methods combine the use of non-invasive skin collecting techniques with one or more assays for determining mitochondrial DNA (mtDNA) aberrations and Melanocortin 1 Receptor (MC1R) variants, thereby providing a comprehensive tool for identifying, predicting and/or monitoring photoageing, ultraviolet radiation (UVR) damage or skin disease. The methods of the invention may also be effective in screening for new therapeutic agents, skin care products and treatment regimes, and may also be useful for monitoring the response of a subject to a preventative or therapeutic treatment.

Claims

1. A diagnostic method for determining the skin state and genetic predisposition of a subject to UVR damage, comprising:

(a) collecting tissue samples from a subject;

(b) assaying a first skin sample for mitochondrial DNA (mtDNA) aberrations;

(c) assaying a second skin sample for one or more melanocortin 1 receptor (MC1R) variants; and

(d) determining the skin state and genetic predisposition of the subject to UVR damage based on the detection of the mtDNA aberrations and MC1R variant(s) in the skin samples.

2. The method of claim 1 wherein the aberration is selected from the group consisting of deletions, substitutions, and insertions.

3. The method of claim 2 wherein the aberration is an mtDNA deletion.

4. The method of claim 3 wherein the deletion is a 3895 by mtDNA deletion between nucleic acids 546 to 4444 of the mtDNA genome.

5. The method of claim 1 wherein the one or more MC1R variants are selected from the group consisting of D84E, R142H, R151C, R160H, D294H, V60L, and V92M.

6. The method of claim 1 wherein at least the first tissue sample is a skin sample obtained using a non-invasive or minimally invasive skin collecting technique.

7. The method of claim 6 wherein the skin sample is collected using a Sterile swab, cotton tip swap, a small gauge needle to collect micro-cores of skin tissue, or a combination thereof.

8. The method of claim 7 wherein the skin is collected from the dermal or epidermal layer of the subject.

9. The method of claim 8 wherein the skin sample is derived from the heel, nose, inner arm, ear, mouth, scalp, chest, shoulder, buttock, back, face, nape of the neck, hand, head, or a combination thereof.

10. Use of the method of claim 1 for predicting photoaging, UVR damage or skin disease.

11. Use of the method of claim 1 for determining a prophylactic or therapeutic treatment for preventing or ameliorating photoaging, UVR damage or skin cancer.

12. A non-invasive method for monitoring photoaging, UVR damage or skin disease, comprising:

(a) collecting a skin sample from a subject using a non-invasive skin sampling technique;

(b) assaying the skin sample for mitochondrial DNA (mtDNA) aberrations at regular intervals over a prescribed period of time; and

(c) determining any changes in mtDNA aberration identified over the prescribed period of time.

13. The method of claim 12 wherein the non-invasive skin collecting technique yields ultra low levels of DNA.

14. The method of claim 13 wherein said ultra low levels of DNA is about 0.1 ng of nucleic acid.

15. A method for monitoring a subject'"'"'s response to a preventative or therapeutic treatment for photoaging, UVR damage or skin disease, comprising:

(a) collecting a first skin sample from a subject;

(b) assaying the first skin sample for mitochondrial DNA (mtDNA) aberrations;

(c) assaying the first skin sample for one or more melanocortin 1 receptor (MC1R) variants;

(d) determining the skin state and genetic predisposition of the subject to UVR damage based on the detection of the mtDNA aberrations and MC1R variant(s) in the first skin sample;

(e) providing a preventative or therapeutic treatment for photoaging, UVR damage or skin disease;

(f) collecting a second skin sample from a subject;

(g) assaying the second skin sample for mitochondrial DNA (mtDNA) aberrations;

(h) repeating steps (f) and (g) at regular intervals over a prescribed period of time; and

(i) comparing the level of mtDNA aberrations between the first skin sample and the skin samples taken at regular intervals to detect changes in mtDNA aberrations, thereby monitoring the effectiveness of the treatment; and

(j) optionally, adjusting the treatment based on the genetic predisposition of the subject and the detected changes in mtDNA aberrations.

16. The method of claim 15 wherein the first skin sample, second skin sample and skin samples taken at regular intervals are obtained using a non-invasive or minimally invasive skin collecting technique.

17. The method of claim 16 wherein the non-invasive or minimally invasive skin collecting technique used to collect the second skin sample and samples taken at regular intervals yields ultra low levels of DNA.

18. The method of claim 17 wherein said ultra low levels of DNA is about 0.1 ng of nucleic acid.

19. The method of claim 15 wherein said regular intervals are biweekly or monthly.

20. A method of screening for an effective therapeutic or cosmeceutic agent for the treatment of photoaging, UVR damage or skin disease, comprising;

(a) collecting a first skin sample from a subject;

(b) assaying the first skin sample for mitochondrial DNA (mtDNA) aberrations;

(c) treating the subject with the therapeutic or cosmeceutic agent;

(d) collecting a second skin sample from a subject following a prescribed period of time;

(e) assaying the second skin sample for mitochondrial DNA (mtDNA) aberrations; and

(f) comparing the level of mtDNA aberrations between the first skin sample and the second skin sample against a control to determine the effectiveness of the therapeutic or comesceutical agent.

21. The method of claim 20 wherein the first skin sample and second skin sample are obtained using a non-invasive or minimally invasive skin collecting technique.

22. A method for determining the level of photodamage of a subject, comprising:

(a) collecting a skin sample from a subject;

(b) assaying the skin sample for mitochondrial DNA (mtDNA) deletions;

(c) comparing the level of mtDNA deletions of the skin sample against a population of mtDNA deletions categorized according to age co-horts, and assigning a photoage to the subject; and

(d) determining the level of photodamage of the subject by comparing the subject'"'"'s chronological age to the assigned photoage.

23. The method of claim 22 where the mitochondrial DNA deletion is the 3895 bp deletion.

24. A diagnostic kit for determining the skin state and genetic predisposition of a subject to UVR damage, comprising:

(a) material for collecting tissue samples; and

(b) suitable primers, probes and reagents for carrying out MC1R genotyping and the detection of mtDNA aberrations.